Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shifting Medicare Part B Drugs To Part D: Legislative Prospects Cloudy

Executive Summary

Democrats on US Senate Health Committee express concern that patient cost sharing could increase significantly with the change.

You may also be interested in...



Democrat-Controlled House Will Turn Up The Volume On Drug Pricing

With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will likely need to dovetail with President Trump’s agenda to advance.

Democrat-Controlled House Will Turn Up The Volume On Drug Pricing

With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will probably need to dovetail with President Trump’s agenda to advance.

Part B Payment Model Indexing Commercial Discounts Proposed By Genentech

Approach offered as alternative to more disruptive changes to Part B's existing buy-and-bill system; more aggressive proposals include new iteration of  competitive acquisition program and moving Part B drug coverage to Part D.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS123291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel